Sanofi presented nine abstracts at the AACR Annual Meeting in Chicago from April 14-18. Building on its strong heritage in oncology, the company aims to share new, early-stage studies highlighting an emerging and dynamic portfolio that encompasses diverse strategies, including immuno-oncology.
Sanofi’s abstracts at AACR includes a late-breaking pre-clinical presentation in partnership with BioNTech highlighting the potential impact of combination treatment with intra-tumoral cytokine mRNAs, an emerging class of immunotherapy medication. Additionally, results on overcoming resistance to an already-established type of immunotherapy, PD-1 (programmed cell death protein 1) inhibitors, was presented. Notably, these data featured Sanofi’s TGF-beta candidate, SAR439459, along with a joint presentation with Evotec on the investigational candidate EVT801, a small molecule inhibitor of VEGFR3 to target myeloid derived suppressor cells (MDSCs) in the tumor microenvironment. Sanofi is also advancing SAR439859, a SERD (selective estrogen receptor degrader) in estrogen-receptor-positive breast cancer and a number of presentations on this candidate was presented.
“Sanofi was excited to share a broad range of promising early-stage science in oncology at AACR 2018,” said Yong-Jun Liu, M.D., Ph.D., Head of Research, Global R&D at Sanofi. “By strengthening our internal research capabilities, and by collaborating with the key therapeutic leaders in this field, we are now able to demonstrate the emerging strength and depth of our oncology pipeline at Sanofi.”
The company is pursuing a breadth of approaches and new technologies to shape its early-stage oncology pipeline, including small molecule therapeutics, next-generation biologics such as antibody drug conjugates, and multi-targeting therapies.
Sanofi’s presentations at AACR 2018 are summarized below.
Late breaking presentation
Sanofi presentation with Evotec
Receive the latest news and updates of upcoming events. Become a free member today.